# Star Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/star-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.star-therapeutics.com
- Total disclosed funding: $415M
- Investors on record: 21

## About

Based in California, US, and founded in 2018 by CEO Adam Rosenthal, Star Therapeutics Inc. is a provider of therapies for multiple rare diseases that share a common pathobiology. This approach allows for the development of therapeutics capable of treating numerous rare diseases with a single therapy. In September 2023, Star Therapeutics Inc. raised USD 90 million in series C funding led by investor Sofinnova Investments, with participation from other investors Agent Capital, Catalio Capital Management, NYBC Ventures, and Qatar Investment Authority, as well as Cormorant Asset Management, Cowen Healthcare Investments, New Leaf Venture Partners, OrbiMed Advisors, RA Capital, Redmile Group, and Westlake Village BioPartners. In September 2025, Star Therapeutics Inc. raised USD 125 million in series D funding co-led by new investors Sanofi Ventures and Viking Global Investors, with participation from other new investors Janus Henderson Investors, Frazier Life Sciences, and GordonMD Global Investments. Returning investors Agent Capital, Blue Owl, Catalio Capital Management, Cormorant Asset Management, GordonMD Global Investments, New Leaf Venture Partners, NYBC Ventures, OrbiMed Advisors, Qatar Investment Authority, RA Capital Management, Redmile Group, Sofinnova Investments, Soleus Capital, Westlake Village BioPartners, and other unspecified investors also participated in the round.

STAR Therapeutics specializes in the development of antibody therapeutics. The company offers a promising solution for patients facing rare diseases with limited treatment options. By combining creativity with scientific rigour, the company accelerates clinical development to bring therapies to patients rapidly. In addition, the firm's portfolio of companies includes Electra Therapeutics, specializing in immunological diseases and cancer treatments, and Vega Therapeutics, dedicated to addressing rare blood disorders, starting with von Willebrand disease (VWD).

The company plans to use the September 2025 funding to support testing of a monthly injection for treating inherited bleeding disorders.

## Funding rounds

- Round, Oct 23, 2026, $200M — Janus Henderson Investors, OrbiMed, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Agent Capital, Soleus Capital, Catalio Capital Management
- Series D, Sep 30, 2025, $125M — OrbiMed Advisors, Sofinnova Investments, New Leaf Venture Partners, Viking Global Investors, Sanofi Ventures, Redmile Group, RA Capital Management, Cormorant Asset Management, Agent Capital, Janus Henderson Investors, Soleus Capital, Westlake Village BioPartners, Catalio Capital Management, Blue Owl, GordonMD Global Investments, NYBC Ventures, Qatar Investment Authority, Frazier Life Sciences
- Series C, Sep 5, 2023, $90M — OrbiMed Advisors, Sofinnova Investments, New Leaf Venture Partners, Qatar Investment Authority, Redmile Group, RA Capital Management, Cormorant Asset Management, Agent Capital, Westlake Village BioPartners, Cowen Healthcare Investments, Catalio Capital Management, NYBC Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C, Series D
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C, Series D
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series C, Series D
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series C, Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C, Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C, Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C, Series D
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series C, Series D
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series C, Series D
- Cowen Healthcare Investments — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C, Series D
- NYBC Ventures (https://capitalatlas.ai/funds/nybc-ventures) — Series C, Series D
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series D
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series D
- Janus Henderson Investors — Series D
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series D
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series D
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series D
- Frazier Life Sciences — Series D
- OrbiMed
- Redmile